Literature DB >> 24600639

Combination of intravitreal bevacizumab and peripheral photocoagulation: an alternative treatment in eales disease.

Juarez Cp1, Gramajo Al1, Luna Jd1.   

Abstract

To report the efficacy of combination therapy (bevacizumab and photocoagulation) in a case of Eales Disease this study has been performed. Bevacizumab (Avastin, 1.25 mg/0.05 ml) was injected intravitreously for the treatment of iris and retinal neovascularization in a 56-year old Hispanic female with photocoagulation treatment to control the recurrence of vitreous haemorrhage. Our results revealed that stabilization of the disease and improvement in visual acuity were achieved without any signs of recurrence. Intravitreal bevacizumab in combination with photocoagulation treatment of ischemic retinal areas may be a good alternative for patients with recurrent vitreous haemorrhage due to Eales disease.

Entities:  

Keywords:  Bevacizumab; Eales disease; Retinal neovascularization; Retinal photocoagulation

Year:  2013        PMID: 24600639      PMCID: PMC3939753     

Source DB:  PubMed          Journal:  Med Hypothesis Discov Innov Ophthalmol        ISSN: 2322-3219


  13 in total

1.  Full panretinal photocoagulation and early vitrectomy improve prognosis of retinal vasculitis associated with tuberculoprotein hypersensitivity (Eales' disease).

Authors:  A M Abu El-Asrar; S A Al-Kharashi
Journal:  Br J Ophthalmol       Date:  2002-11       Impact factor: 4.638

2.  Therapeutic effects of laser photocoagulation and/or vitrectomy in Eales' disease.

Authors:  M H Dehghan; H Ahmadieh; M Soheilian; M Azarmina; A Mashayekhi; J Naghibozakerin
Journal:  Eur J Ophthalmol       Date:  2005 May-Jun       Impact factor: 2.597

3.  Rapid regression of disc and retinal neovascularization in a case of Eales disease after intravitreal bevacizumab.

Authors:  Atul Kumar; Subijay Sinha
Journal:  Can J Ophthalmol       Date:  2007-04       Impact factor: 1.882

4.  Proinflammatory cytokines and angiogenic and anti-angiogenic factors in vitreous of patients with proliferative diabetic retinopathy and eales' disease.

Authors:  Ponnalagu Murugeswari; Dhananjay Shukla; Anand Rajendran; Ramasamy Kim; Perumalsamy Namperumalsamy; Veerappan Muthukkaruppan
Journal:  Retina       Date:  2008-06       Impact factor: 4.256

Review 5.  Eales' disease.

Authors:  T Das; J Biswas; A Kumar; P N Nagpal; P Namperumalsamy; B Patnaik; H K Tewari
Journal:  Indian J Ophthalmol       Date:  1994-03       Impact factor: 1.848

6.  [Eales disease: a case report in Burkina Faso].

Authors:  J W Diallo; Z Nikiema; A Daboue; H Tieno; N Meda; G R Kan
Journal:  J Fr Ophtalmol       Date:  2011-07-30       Impact factor: 0.818

7.  Role of intravitreal bevacizumab in Eales disease with dense vitreous hemorrhage: a prospective randomized control study.

Authors:  Sourabh Dileep Patwardhan; Rajvardhan Azad; Bhavin Mahendra Shah; Yograj Sharma
Journal:  Retina       Date:  2011-05       Impact factor: 4.256

8.  Intravitreal injection of bevacizumab in Eales disease.

Authors:  Cem Küçükerdönmez; Yonca A Akova; Gürsel Yilmaz
Journal:  Ocul Immunol Inflamm       Date:  2008 Jan-Feb       Impact factor: 3.070

9.  Role of intravitreal bevacizumab in the management of Eales' disease.

Authors:  Bhuvan Chanana; Raj Vardhan Azad; Sourabh Patwardhan
Journal:  Int Ophthalmol       Date:  2009-01-23       Impact factor: 2.031

10.  Intravitreal bevacizumab as an adjunct to vitrectomy in advanced Eales' disease.

Authors:  Meenakshi Thakar; Naina R Bamrolia; Usha Kaul Raina; Basudeb Ghosh
Journal:  J Ophthalmic Inflamm Infect       Date:  2011-11-17
View more
  3 in total

1.  VISION 2020: The Right to Sight in 7 Years?

Authors:  Van C Lansingh; Kristen A Eckert
Journal:  Med Hypothesis Discov Innov Ophthalmol       Date:  2013

2.  Role of Intravitreal Bevacizumab in Management of Eale's Disease.

Authors:  Mohammad Asim Mehboob; Muhammad Tahir; Huma Batool
Journal:  Pak J Med Sci       Date:  2018 Mar-Apr       Impact factor: 1.088

Review 3.  Neovascular Macular Degeneration: A Review of Etiology, Risk Factors, and Recent Advances in Research and Therapy.

Authors:  Arunbalaji Pugazhendhi; Margaret Hubbell; Pooja Jairam; Balamurali Ambati
Journal:  Int J Mol Sci       Date:  2021-01-25       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.